Progressive resistance training for adolescents with cerebral palsy: the STAR randomized controlled trial by Ryan, Jennifer M et al.
This is a peer-reviewed, final published version of the following in press document, © 2020 The Authors. 
Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith 
Press. This is an open access article under the terms of the Creative Commons Attribution License, which 
permits use, distribution and reproduction in any medium, provided the original work is properly cited: Ryan, 
J.M., Lavelle, G., Theis, N., Noorkoiv, M., Kilbride, C., Korff, T., Baltzopoulos, V., Shortland, A., Levin, W. 
and (2020), Progressive resistance training for adolescents with cerebral palsy: the STAR randomized 
controlled trial. Dev Med Child Neurol. doi:10.1111/dmcn.14601 and is licensed under Creative Commons: 
Attribution 4.0 license:
Ryan, Jennifer M, Lavelle, Grace, Theis, Nicola ORCID: 0000-0002-0775-
1355, Noorkoiv, Marika, Kilbride, Cherry, Korff, Thomas, Baltzopoulos, 
Vasilios, Shortland, Adam and Levin, Wendy (2020) Progressive 
resistance training for adolescents with cerebral palsy: the STAR 
randomized controlled trial. Developmental Medicine and Child Neurology. 
doi:10.1111/dmcn.14601 (In Press) 
Official URL: https://onlinelibrary.wiley.com/doi/full/10.1111/dmcn.14601
DOI: http://dx.doi.org/10.1111/dmcn.14601
EPrint URI: http://eprints.glos.ac.uk/id/eprint/8517
Disclaimer 
The University of Gloucestershire has obtained warranties from all depositors as to their title in the material 
deposited and as to their right to deposit such material.  
The University of Gloucestershire makes no representation or warranties of commercial utility, title, or fitness 
for a particular purpose or any other warranty, express or implied in respect of any material deposited.  
The University of Gloucestershire makes no representation that the use of the materials will not infringe any 
patent, copyright, trademark or other property or proprietary rights.  
The University of Gloucestershire accepts no liability for any infringement of intellectual property rights in any 
material deposited but will remove such material from public view pending investigation in the event of an 
allegation of any such infringement. 
PLEASE SCROLL DOWN FOR TEXT.
DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY ORIGINAL ARTICLE
Progressive resistance training for adolescents with cerebral
palsy: the STAR randomized controlled trial
JENNIFER M RYAN1,2* | GRACE LAVELLE2,3* | NICOLA THEIS4 | MARIKA NOORKOIV2 | CHERRY KILBRIDE2
| THOMAS KORFF5 | VASILIOS BALTZOPOULOS6 | ADAM SHORTLAND7 | WENDY LEVIN8 |
THE STAR TRIAL TEAM**
1 Department of Public Health and Epidemiology, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland. 2 College of Health and Life Sciences, Brunel
University London, London; 3 Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London; 4 School of Sport and Exercise, University of
Gloucestershire, Gloucester; 5 Research and Development, Frogbikes, Ascot; 6 Research Institute for Sport and Exercises Sciences, Liverpool John Moores
University, Liverpool; 7 One Small Step Gait Laboratory, Guy’s Hospital, London; 8 Department of Physiotherapy,Swiss Cottage School and Development and
Research Centre, London, UK.
Correspondence to Jennifer M. Ryan, RCSI, Beaux Lane House, Lower Mercer Street, Dublin 2, D02DH60, Ireland. E-mail: jenniferryan@rcsi.com
*Joint first authors.
**Members of the STAR Trial Team are listed in the Acknowledgements.
PUBLICATION DATA
Accepted for publication 6th May 2020.
Published online
ABBREVIATIONS
GMFM-66 Gross Motor Function Measure
66
NNcost Net nondimensional oxygen
cost
AIM To evaluate the effect of progressive resistance training of the ankle plantarflexors on
gait efficiency, activity, and participation in adolescents with cerebral palsy (CP).
METHOD Sixty-four adolescents (10–19y; 27 females, 37 males; Gross Motor Function
Classification System [GMFCS] levels I–III) were randomized to 30 sessions of resistance training
(10 supervised and 20 unsupervised home sessions) over 10 weeks or usual care. The primary
outcome was gait efficiency indicated by net nondimensional oxygen cost (NNcost). Secondary
outcomes included physical activity, gross motor function, participation, muscle strength, muscle
and tendon size, and muscle and tendon stiffness. Analysis was intention-to-treat.
RESULTS Median attendance at the 10 supervised sessions was 80% (range 40–100%). There
was no between-group difference in NNcost at 10 (mean difference: 0.02, 95% confidence
interval [CI] –0.07 to 0.11, p=0.696) or 22 weeks (mean difference: –0.08, 95% CI –0.18 to 0.03,
p=0.158). There was also no evidence of between-group differences in secondary outcomes
at 10 or 22 weeks. There were 123 adverse events reported by 27 participants in the
resistance training group.
INTERPRETATION We found that 10 supervised sessions and 20 home sessions of progressive
resistance training of the ankle plantarflexors did not improve gait efficiency, muscle
strength, activity, participation, or any biomechanical outcome among adolescents with CP.
Cerebral palsy (CP) is characterized by atypical fine and
gross motor function, which results in activity limitations
and participation restrictions.1,2 Many young adults with
CP experience a deterioration in mobility with age,3 which
may be attributed to progressive loss of muscle strength
and reduced gait efficiency.4,5 Progressive resistance train-
ing has potential to improve gait efficiency and muscle
strength and hence prevent or delay deterioration in
mobility in young adulthood.
Strength or resistance training is one of the most fre-
quently used interventions among physiotherapists to man-
age lower-limb function in adolescents with CP.6 Despite
the potential for progressive resistance training to improve
strength and gait efficiency among adolescents with CP,
there is little evidence to date to support its effect on any
level of functioning, as classified by the World Health
Organization’s International Classification of Functioning,
Disability and Health framework.7 However, there are sev-
eral limitations with the current evidence base including
delivery of a potentially inadequate training stimulus, fail-
ure to describe fidelity to the intervention, few studies
examining outcomes at all levels of the International Clas-
sification of Functioning, Disability and Health framework,
and few studies reporting adverse events.7 Progressive
resistance training needs to be provided at an adequate vol-
ume (i.e. the product of sets and repetitions) and with ade-
quate resistance in order to overload the muscle and
increase strength.8 It is particularly important to progress
intensity throughout the programme, as the muscle adapts
and strengthens, so that it is continuously overloaded.8
Failure to deliver resistance training at sufficient intensity
for the duration of the programme may explain why only
small improvements in muscle strength have been observed
in trials to date.7
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In addition, there is large variation in muscle groups tar-
geted by resistance training, with most studies targeting knee
extensors7 despite muscle strength and volume deficits being
particularly pronounced for ankle plantarflexors in CP.9,10
Ankle plantarflexor strength is a strong predictor of walking
endurance, step cadence, and gross motor function among
young people with CP,11,12 and thus a progressive resistance
training programme targeting ankle plantarflexors may
improve walking function and gross motor function. Target-
ing plantarflexors may also specifically improve gait effi-
ciency through biomechanical mechanisms.13 People with
CP have a high degree of triceps surae muscle stiffness com-
pared to Achilles tendon stiffness.14 Progressive resistance
training can increase tendon stiffness,15 which may promote
a more efficient muscle tendon interaction and muscle con-
traction during gait.16 Additionally, increasing the size and
strength of the plantarflexor muscles may improve knee
extension in the stance phase of walking and aid propulsion
of the lower limb in pre-swing, resulting in greater walking
efficiency with a more erect alignment of the skeleton. This,
in turn, may reduce unnecessary internal work and improve
ankle power generation.17
The aims of the Strength Training for Adolescents with
ceRebral palsy (STAR) trial were to: (1) evaluate the effect
of progressive resistance training of the ankle plantarflexors
on gait efficiency, activity, and participation in adolescents
with CP; and (2) to determine the biomechanical adapta-
tions that occur after resistance training.
METHOD
Study design and participants
The STAR trial was a multicentre randomized controlled
trial comparing a 10-week progressive resistance training
programme to usual care. Full details of the methods are
provided in the protocol.13 Adolescents with CP were
recruited from eight National Health Service trusts in
England, a special education needs school, a university, a
primary care organization, national organizations for peo-
ple with disabilities, and by word of mouth. Inclusion cri-
teria were a diagnosis of spastic CP, aged 10 to 19 years,
ability to walk independently with or without a mobility
aid (i.e. Gross Motor Function Classification System
[GMFCS] levels I–III), and an ability to activate the ankle
plantarflexors as determined by palpation. Adolescents
were excluded if they had orthopaedic surgery of the lower
limbs in the past 12 months, had botulinum neurotoxin A
injections or serial casting in the past 6 months, or had
insufficient cognition to comply with assessment proce-
dures and the training programme. Participants aged 16
years and over gave written informed consent. Participants
under 16 years of age gave written informed assent and a
parent or guardian provided written informed consent.
The trial was approved by Brunel University London’s
College of Health and Life Sciences Research Ethics
Committee and the Surrey Borders Research Ethics Com-
mittee (ref: 15/LO/0843). Trial registration number was
ISRCTN90378161.
Randomization
Random allocation was computer generated with variable
(random) block length of two or four, and stratification by
GMFCS level (levels I–II and level III). The randomization
schedule was generated by an individual independent to
the study before recruitment. The same individual placed
allocation of participants in sequentially numbered opaque
sealed envelopes. The trial manager revealed allocation,
and informed participants and therapists, after participants
completed the baseline assessment.
Intervention
The intervention, which is described in detail in the proto-
col,13 was based on guidelines for progressive resistance
training in young people with typical development.8 Ado-
lescents in the resistance training programme completed
10 supervised sessions and 20 home sessions of resistance
training over 10 weeks. Exercises, which targeted the ankle
plantarflexors (primarily gastrocnemius), are described in
Figure S1 (online supporting information) and Table S1
(online supporting information). Unilateral exercises were
performed where possible. A standardized programme was
used to progress the intensity of the exercises, with resis-
tance increasing from 12 repetition maximum to 6 repeti-
tion maximum and sets increasing from 4 to 8 over 10
weeks (Table S2, online supporting information). At the
first session, the therapist identified a suitable exercise or
exercises and an appropriate resistance for the participant
depending on their initial strength, balance, and range of
motion, in order to achieve the prescribed intensity (e.g. 4
sets at 12 repetition maximum in week 1). Resistance was
added using free weights on a leg press or hack squat
machine, weighted vests, ankle weights, or resistance band.
Participants performed the exercise or a combination of
exercises during the supervised session and home sessions
to achieve the prescribed intensity for that week (e.g. 4 sets
at 12 repetition maximum in each session during week 1).
Resistance was added incrementally at each supervised ses-
sion to ensure that the participant completed the pre-
scribed number of repetitions at the supervised and home
session to fatigue and was therefore exercising at the pre-
scribed intensity. As participants did not have access to the
hack squat machine or leg press machine at home, the
therapist prescribed one or more of the remaining exercises
to complete at home (i.e. the standing straight knee calf
raise or the seated straight knee calf press against the resis-
tance band), depending on the participant’s strength. Resis-
tance was added (e.g. using a weighted vest or ankle
weights) to ensure the participant completed the prescribed
What this paper adds
• Thirty sessions of progressive resistance training of the ankle plantarflexors
over 10 weeks did not improve gait efficiency among ambulatory adoles-
cents with cerebral palsy.
• Resistance training did not improve muscle strength, activity, or participation.
• Ninety percent of participants experienced an adverse event.
• Most adverse events were expected and no serious adverse events were
reported.
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intensity. As the resistance band was not adequate to
achieve the desired intensity for the majority of partici-
pants, most participants were prescribed a standing straight
knee calf raise. Participants received a diary each week with
pictures and instructions outlining the exercise(s) to be
completed at home, including the number of repetitions,
sets, type, and amount of resistance. Participants recorded
home exercise completion and adverse events in this diary.
The programme was delivered to participants either indi-
vidually or in groups of up to three people by one or two
physiotherapists, depending on group size. The research
team provided training to therapists to deliver the pro-
gramme, which included information on both the theoreti-
cal underpinning and practical application of the
programme. The trial manager also attended the first ses-
sion to support the therapists to deliver the intervention and
attended additional sessions if requested by the therapist. At
the start of each supervised session, therapists collected the
diary and asked participants how many home exercise ses-
sions they had completed and if they had experienced any
adverse events since the last session such as muscle soreness,
fatigue, or a fall. Therapists recorded the following infor-
mation for each session in a standardized form: a descrip-
tion of the exercise(s) completed; number of repetitions and
sets performed; type and amount of resistance applied;
whether or not each exercise was progressed and reasons for
non-progression; home exercise(s) prescribed including rep-
etitions, sets, and resistance; home exercise completion; and
adverse events that occurred during the session and at
home, in the past week. An adverse event was considered
serious if it resulted in death, was life-threatening, required
hospitalization or prolongation of existing hospitalization,
or resulted in persistent or significant disability or incapac-
ity. Adverse events were not monitored among participants
randomized to the usual care control group.
Usual care
Participants in both the resistance training and usual care
control group were instructed to continue with their usual
physiotherapy and activities, provided it did not include
progressive resistance training. No participant reported
that progressive resistance training was part of their usual
care. Physiotherapy provision during the 22 weeks was
assessed using a modified version of the Client Service
Receipt Inventory at 10 and 22 weeks.18
Outcomes
The assessments conducted at baseline, 10, and 22 weeks
post-randomization are described in the protocol.13 Assess-
ments were conducted during a face-to-face appointment at
Brunel University London, supplemented by postal or tele-
phone questionnaires where required. The young person
was allowed to ask their parent/guardian for assistance to
complete questionnaires if required. Assessors were masked
to group allocation for all outcomes except for the Gross
Motor Function Measure 66 (GMFM-66). Performance of
the GMFM-66 was video-recorded. A specialist paediatric
physiotherapist, with experience of scoring the GMFM-66
and masked to group allocation, scored recordings.
The primary outcome was gait efficiency indicated by net
nondimensional oxygen cost (NNcost) calculated from
oxygen consumption measured during 6 minutes of over-
ground walking and 10 minutes of rest using a portable
metabolic system (Cosmed K5, Rome, Italy).19 Further
detail on the calculation of NNcost is provided in
Appendix S1 (online supporting information). Secondary
outcomes were physical activity, participation, gait speed,
gross motor function, muscle-tendon mechanics, and knee
and ankle flexion angle at mid-stance. Average daily time in
moderate-to-vigorous physical activity, average daily time in
light physical activity, and average daily percentage time in
sedentary behaviour were assessed objectively using an
accelerometer (Actigraph wGT3X, Pensacola, FL, USA)
worn for 7 days. Further details on identification of non-
wear-time, criteria for valid wear-time, and classification of
activity counts are provided in Appendix S2 (online support-
ing information). Participation was measured using the
Assessment of Life Habits Questionnaire (range 0–9; higher
score indicates greater participation).20 Gait speed was
measured as the average of three trials of walking at self-
selected speed over 10m. Gross motor function was assessed
using dimensions D and E of the GMFM-66; a higher score
indicates better function.21 The following outcomes were
assessed on the participant’s affected leg in the case of uni-
lateral CP, the most affected leg in the case of bilateral CP,
or the right leg if a participant reported that both sides were
equally affected. Achilles tendon cross-sectional area and
medial gastrocnemius muscle volume were assessed using a
three-dimensional freehand ultrasonography method.22
Change in medial gastrocnemius muscle length was mea-
sured with a combination of 3D motion analysis and 2D
ultrasound.14 Muscle strength, represented by torque, was
measured on an isokinetic dynamometer (Cybex Inc., Ron-
konkoma, NY, USA) as the best of three maximal voluntary
isometric plantarflexion contractions. Achilles tendon stiff-
ness, Achilles tendon Young’s modulus, and medial gastroc-
nemius muscle stiffness were calculated as described in the
protocol.13 Ankle and knee flexion angle at mid-stance were
measured from a full body motion analysis marker set
during treadmill walking.13
Data analysis
A sample size of 27 participants in each group was required
to detect a difference of 0.17 in NNcost with a standard
deviation of 0.31,23 using a 5% significance level and 80%
power, and assuming a Pearson’s correlation coefficient of
0.7 between baseline and follow-up NNcost. The distribu-
tion of continuous numeric data were examined using quan-
tile–quantile plots. Primary analyses were intention-to-treat.
Secondary ‘per-protocol’ analyses were conducted using
data from participants who attended ≥70% of intervention
sessions and completed follow-up to 22 weeks. Analyses
were conducted using Stata (version 15.0; Statcorp, College
Station, TX, USA). Linear mixed models adjusted for
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baseline scores and GMFCS level were used to assess the
effect of the intervention. Interaction terms between treat-
ment group and time, and GMFCS level and time, were
included in the model; the treatment effect therefore repre-
sents the difference between the resistance training group
and usual care group adjusted for baseline values and
GMFCS level. We adjusted for GMFCS level as there is
evidence that adjustment for balancing variables used in
stratified randomization is required to obtain correct p-
values and confidence intervals.24 We conducted a prespeci-
fied subgroup analysis by including an interaction term to
determine if treatment effect differed according to GMFCS
level. We additionally conducted a post hoc subgroup anal-
ysis to determine if treatment effect differed according to
anatomical distribution (i.e. bilateral/unilateral). We further
conducted a sensitivity analysis by repeating primary analy-
ses and adjusting for any major imbalances in prognostic
factors between groups. The distribution of residuals from
linear mixed models was examined using quantile–quantile
plots; there was no evidence that residuals did not follow a
normal distribution for any model.
RESULTS
Between November 2015 and May 2017, 266 potentially
eligible participants received information about the study.
Of these, two were excluded for receiving surgery in the
past 12 months and 200 declined to participate. Reasons
for refusal included the parent or young person having
insufficient time to commit to a 10-week programme and
inability to travel to the class. Sixty-four participants were
included (Fig. S2, online supporting information). Baseline
characteristics are presented in Tables 1 and 2. The groups
were similar on baseline characteristics, except for sex,
GMFCS level, and distribution. There were fewer females
and fewer people with unilateral CP in the resistance train-
ing group. There was a higher proportion of people in
GMFCS level I and a lower proportion of people in
GMFCS level II in the resistance training group compared
to the control group.
Fifty-five (86%) and 52 people (81%) attended the 10
and 22 week assessments respectively (Fig. S2). Characteris-
tics of those retained at 22 weeks and those lost to follow-
up are presented in Table S3 (online supporting informa-
tion). Missing data ranged from 0% to 42% at baseline, 6%
to 61% at 10 weeks, and 12% to 58% at 22 weeks. Reasons
for missing data included lost to follow-up, incomplete
questionnaires, equipment malfunction, and failure to
return the accelerometer. Participants wore the accelerome-
ter for a median of 7 days (range 2–7). Wear-time is
described in Table S4 (online supporting information).
Table 1: Baseline characteristics, usual care control group
Usual care control group (n=31)
n (%) Mean (SD) Median (range)
Age, y:mo 31 13:11 (2:6) 14 (10–19)
Female 14 (45)
Height, cm 31 154.1 (12.1) 154.0 (131.5–180.9)
Mass, kg 31 50.4 (12.1) 51.5 (29.0–75.6)
GMFCS level
I 13 (42)
II 13 (42)
III 5 (16)
Distribution
Unilateral 17 (55)
Bilateral 14 (45)
Self-reported orthotic wear 14 (45)
NNcost 31 0.53 (0.35) 0.42 (0.18–2.04)
Physical activity
Daily MVPA, min 30 (97) 56.4 (31.9) 60.8 (3.7–139.5)
Daily LPA, min 30 (97) 193.9 (54.5) 188.9 (70.9–311.2)
Daily sedentary time, % 30 (97) 67.3 (10.7) 67.2 (40.8–92.1)
Daily step count 30 (97) 5941.9 (2578.1) 6564.4 (549.6–12035.8)
Life-H score 22 (71) 6.4 (1.7) 6.6 (3.2–8.5)
GMFM-66 D, % 29 (94) 84.6 (20.0) 89.7 (25.6–100.0)
GMFM-66 E, % 29 (94) 79.3 (26.5) 91.7 (15.3–100.0)
Gait speed, m.s-1 31 1.1 (0.3) 1.1 (0.3–1.5)
Maximal voluntary contraction, Nm 31 28.6 (18.6) 24.7 (2.6–74.1)
Medial gastrocnemius muscle volume, cm3 18 (58) 70.9 (31.3) 65.5 (28.4–134.8)
Achilles tendon CSA, cm2 24 (77) 0.43 (0.09) 0.41 (0.29–0.60)
Medial gastrocnemius muscle stiffness, Nm.mm-1 26 (84) 1.63 (0.82) 1.34 (0.56–3.45)
Achilles tendon stiffness, N.mm-1 27 (87) 172.0 (94.9) 158.5 (74.6–556.4)
Achilles tendon Young’s modulus, MPa 24 (77) 813.9 (370.0) 744.0 (341.9–1790.5)
Ankle flexion angle, ° 25 (81) –13.3 (6.7) –13.8 (–23.4 to 1.6)
Knee flexion angle, ° 25 (81) –9.0 (15.3) 4.6 (–47.9 to 16.3)
SD, standard deviation; GMFCS, Gross Motor Function Classification System; NNcost, net nondimensional cost; MVPA, moderate-to-vigor-
ous physical activity; LPA, light physical activity; Life-H, Assessment of Life Habits; GMFM, Gross Motor Function Measure; CSA, cross-sec-
tional area.
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Eighteen therapists delivered the programme at eight
sites. Table 3 outlines details of the resistance training
programme and usual care received by both groups over
10 weeks. Median attendance was 80% (range 40–100%)
of a possible 10 supervised sessions. Approximately 85%
of participants attended at least 70% of supervised ses-
sions; 27.3% attended all 10 sessions, 18.2% attended
nine sessions, 21.2% attended eight sessions, and 18.2%
attended seven sessions. The median percentage of home
sessions completed, out of a possible 20 sessions, was
80% (range 10–115%). Approximately 73% of participants
completed at least 70% of home sessions. Overall, the
median percentage of supervised and home sessions com-
pleted, out of a possible 30, was 80% (range 30–110%).
Table 3: Description of treatment and usual care received
Usual care group Resistance training group
Treatment received
Attendance, median (range)a – 80 (40–100)
Attended ≥70% supervised sessions, n (%) – 28 (84.9)
Median (range) Number of classes progressed, median (range)b – 7 (2–9)
Exercises progressed,b n (%) – 8 (24.2)
Home sessions completed, median (range)c – 80 (10–115)
Completed ≥70% home sessions, n (%) – 24 (72.7)
Sessions completed, median (range)d – 80 (30–110)
Completed ≥70% sessions (supervised and home), n (%) – 25 (75.8)
Usual care received during 22 weeks
Self-reported activity participation (≥1 per week), n (%) 19 (83) 24 (77)
Received physiotherapy at least once, n (%) 14 (58) 15 (52)
Number of physiotherapy sessions, median (range) 2 (0–31) 1 (0–48)
aAs a percentage of 10 possible supervised sessions. bDefined as progressed at least 8 of 9 supervised sessions. cAs a percentage of 20
possible home sessions; note some participants completed more than the prescribed sessions. dAs a percentage of 30 possible supervised
sessions; note some participants completed more than the prescribed sessions.
Table 2: Baseline characteristics, resistance training group
Resistance training group (n=33)
n (%) Mean (SD) Median (range)
Age, y:mo 33 13:6 (2:7) 13 (10–19)
Female 13 (39)
Height, cm 33 154.5 (13.3) 157.0 (133.7–178.8)
Mass, kg 33 48.5 (15.1) 47.5 (27.4–78.5)
GMFCS level
I 16 (49)
II 12 (36)
III 5 (15)
Distribution
Unilateral 14 (42)
Bilateral 19 (58)
Self-reported orthotic wear 15 (46)
NNcost 32 (97) 0.55 (0.21) 0.48 (0.33–1.00)
Physical activity
Daily MVPA, min 30 (91) 53.4 (24.5) 56.3 (4.8–118.6)
Daily LPA, min 30 (91) 181.6 (57.9) 175.2 (70.7–354.7)
Daily sedentary time, % 30 (91) 67.7 (11.2) 68.2 (45.4–90.6)
Daily step count 30 (91) 5492.0 (2669.3) 5553.0 (565.9–11562.8)
Life-H score 29 (88) 7.0 (1.7) 7.4 (3.6–9.0)
GMFM-66 D, % 33 80.6 (29.2) 92.3 (0.0–100.0)
GMFM-66 E, % 33 78.9 (30.2) 93.1 (0.0–100.0)
Gait speed, m.s-1 33 1.1 (0.2) 1.1 (0.4–1.6)
Maximal voluntary contraction, Nm 32 (97) 30.5 (17.5) 30.6 (8.4–74.0)
Medial gastrocnemius muscle volume, cm3 19 (58) 61.3 (21.0) 55.4 (32.7–101.8)
Achilles tendon CSA, cm2 27 (82) 0.42 (0.08) 0.40 (0.26–0.55)
Medial gastrocnemius muscle stiffness, Nm.mm-1 27 (82) 2.24 (2.21) 1.66 (0.98–12.25)
Achilles tendon stiffness, N.mm-1 29 (88) 154.6 (104.6) 136.0 (54.3–587.9)
Achilles tendon Young’s modulus, MPa 28 (85) 757.2 (579.1) 652.8 (297.9–3392.3)
Ankle flexion angle, ° 26 (79) –15.1 (9.8) –14.8 (–43.3 to 2.4)
Knee flexion angle, ° 26 (79) –6.8 (11.3) –6.1 (–30.4 to 11.3)
SD, standard deviation; GMFCS, Gross Motor Function Classification System; NNcost, net nondimensional cost; MVPA, moderate-to-vigor-
ous physical activity; LPA, light physical activity; Life-H, Assessment of Life Habits; GMFM, Gross Motor Function Measure;CSA, cross-
sectional area.
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Approximately 76% of participants completed at least
70% of the 30 sessions.
Exercises were progressed at a median of 7 out of a pos-
sible 9 classes (range 2–9). Reasons for non-progression
were: participants reported resistance was too heavy; poor
technique; not obtaining full range of movement; lower-
limb muscle or joint pain; unable to add additional weight
to weighted vest because it was full; unable to add addi-
tional weight to weighted vest because it was causing
shoulder or back pain; fatigue. A slightly higher proportion
of participants in the usual care group reported participat-
ing in physical activities at least once per week over the 22
weeks (Table 3). The proportion of people receiving phys-
iotherapy was also slightly higher in the usual care group.
In total, 123 adverse events were reported by 27 partici-
pants in the resistance training group (Table 4). The most
common types of adverse event reported by participants
were lower-limb muscle soreness (70%), lower-limb pain
(55%), shoulder pain due to weighted vest (18%), a fall
(15%), and lower-limb muscle cramp (15%). Falls did not
occur during the class and therefore may be unrelated to
the intervention.
Treatment effects
There was no evidence of between-group differences in gait
efficiency, physical activity, participation, gross motor func-
tion, gait speed, or muscle strength at 10 and 22 weeks
(Table 5). There was also no evidence of between-group dif-
ferences in any additional secondary outcome (Table S5,
online supporting information). We identified some sub-
group effects. Among those in GMFCS level II, there was
evidence of a between-group difference in Achilles tendon
Young’s modulus at 10 weeks in favour of the intervention
(adjusted mean difference: 206.00MPa, 95% CI 15.90–
396.09MPa, p=0.034). At 22 weeks, there was very weak sta-
tistical evidence that among participants in GMFCS level II,
participants in the resistance training group had lower
NNcost (adjusted mean difference: –0.16, 95% CI –0.32 to
0.01, p=0.055) and higher maximal voluntary isometric plan-
tarflexion contraction (adjusted mean difference: 11.12Nm,
95% CI –0.56 to 22.81Nm; p=0.062) compared to the con-
trol group, indicating more efficient gait and greater
strength. There was also evidence that among participants in
GMFCS level II, those in the resistance training group had
greater medial gastrocnemius muscle volume at 22 weeks
compared to the control group (adjusted mean difference:
12.17cm3, 95% CI 3.64–20.71cm3, p=0.005). Further, there
was very weak evidence that among those in GMFCS level
III, Assessment of Life Habits Questionnaire score was
higher for participants in the resistance training group at 22
weeks compared to the control group (adjusted mean differ-
ence: 1.83, 95% CI –0.04 to 3.70, p=0.055). Among those
with bilateral CP, NNcost was lower in the exercise group
compared to the control group at 22 weeks, indicating more
efficient gait (adjusted mean difference: –0.17, 95% CI –0.32
to –0.03, p=0.022). Among those with bilateral CP there was
also evidence of greater knee flexion angles in the interven-
tion group compared to the control group at 22 weeks (ad-
justed mean difference: –10.94 degrees, 95% CI –17.09 to
–4.78 degrees, p<0.001). In those with unilateral CP, moder-
ate-to-vigorous physical activity, step-count, and knee flex-
ion angle during mid-stance were higher in those in the
exercise group compared to the control group at 10 weeks
(adjusted mean difference in moderate-to-vigorous physical
activity: 14.3min, 95% CI 2.0–26.6min, p=0.022; adjusted
mean difference in step-count: 1193.6 steps/min, 95% CI
–12.3 to 2399.6 steps/min, p=0.052; adjusted mean differ-
ence in knee flexion angle: 5.32 degrees, 95% CI 0.61–10.03
degrees, p=0.027).
Sensitivity analysis
Adjusting for sex in addition to GMFCS level did not
result in different conclusions than those obtained from
primary analysis (Table S6, online supporting information).
Per-protocol analysis was conducted using data from 45
people who completed the study to 22 weeks and were
compliant with at least 70% of the sessions, if they were in
the resistance training group. There was very weak evi-
dence of greater maximal voluntary isometric plantarflexion
contraction (adjusted mean difference: 7.18Nm, 95% CI
–0.48 to 14.83Nm, p=0.066) and some evidence of greater
knee flexion angles during mid-stance (adjusted mean dif-
ference: –4.62 degrees, 95% CI –8.90 to –0.33 degrees,
p=0.035) in the resistance training group at 22 weeks com-
pared to the control group (Table S7, online supporting
information).
DISCUSSION
We found no evidence that 10 supervised sessions and 20
unsupervised sessions of progressive resistance training
over 10 weeks of the ankle plantarflexors changed gait effi-
ciency, muscle strength, activity as assessed by habitual
physical activity, gross motor function, and gait speed, or
Table 4: Number and type of adverse events reported by participants in
the resistance training group
Adverse
events
(n=123)a
People
reporting at
least one
event
(n=27)b
Lower-limb muscle soreness 41 (33) 23 (70)
Lower-limb pain 37 (30) 18 (55)
Fall 18 (15) 5 (15)
Lower-limb muscle cramp 7 (6) 5 (15)
Shoulder pain due to weighted
vest
7 (6) 6 (18)
Chest pain 5 (4) 1 (3)
Back pain 3 (2) 3 (9)
Lower-limb stiffness 2 (2) 1 (3)
Arm injury 1 (1) 1 (3)
Ankle sprain 1 (1) 1 (3)
Stomach ache 1 (1) 1 (3)
Data are n (%). aPercentage of total adverse events reported. bPer-
centage of 33 participants in resistance training group.
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participation among adolescents with CP. Similarly, we
found no evidence of changes in any biomechanical out-
comes including muscle volume and tendon cross-sectional
area, muscle and tendon stiffness, or knee and ankle flexion
angle during mid-stance of gait. Ninety percent of partici-
pants experienced at least one adverse event. However,
adverse events were not serious and the majority of events
were lower-limb muscle soreness, which may be considered
an expected effect of progressive resistance training. To
date, reporting of adverse events in trials of exercise for
CP has been poor. A recent review found that 50% of tri-
als of resistance training for people with CP did not state
whether they recorded adverse events.7 However, where
reported, similar adverse events have been noted in previ-
ous trials including shoulder pain from a weighted back-
pack, foot and ankle discomfort, and muscle soreness.7
No randomized control trial to date has examined the
effects of progressive resistance training on gait efficiency.
Recent studies found that fatigue was increased in gastroc-
nemius medialis during walking among children with CP25
Table 5: Treatment effects at 10 and 22 weeks
Usual care control group Resistance training group Difference in meansa (95% CI); p
NNcost
10 weeks 0.47 (0.39–0.55) 0.55 (0.45–0.66) 0.02 (–0.07 to 0.11); 0.696
n (%)b 21 (91.3) 29 (90.6)
22 weeks 0.52 (0.41–0.63) 0.51 (0.40–0.62) –0.08 (–0.18 to 0.03); 0.158
n (%)c 20 (87.0) 25 (86.2)
Daily moderate-to-vigorous activity, min
10 weeks 49.4 (37.1–61.6) 54.4 (43.0–65.8) 5.07 (–3.88 to 14.02); 0.267
n (%) 21 (91.3) 25 (78.1)
22 weeks 49.0 (36.8–61.3) 50.0 (36.3–63.6) –1.39 (–13.28 to 10.51); 0.819
n (%) 19 (82.6) 21 (72.4)
Daily light activity, min
10 weeks 186.8 (165.4–208.2) 164.1 (141.3–187.0) –1.59 (–21.40 to 18.23); 0.875
n (%) 21 (91.3) 25 (78.1)
22 weeks 183.7 (159.1–208.2) 151.0 (124.5–177.5) –9.48 (–38.85 to 19.88); 0.527
n (%) 19 (82.6) 21 (72.4)
Daily sedentary time, %
10 weeks 68.8 (65.3–72.3) 70.3 (65.9–74.7) –0.41 (–3.17 to 2.35); 0.771
n (%) 21 (91.3) 25 (78.1)
22 weeks 68.8 (64.7–72.9) 71.8 (66.2–77.3) 1.92 (–2.28 to 6.12); 0.370
n (%) 19 (82.6) 21 (72.4)
Daily step-count
10 weeks 5647.0 (4525.1–6768.9) 5465.5 (4412.2–6518.9) 281.87 (–604.11 to 1167.89); 0.533
n (%) 21 (91.3) 25 (78.1)
22 weeks 5625.1 (4343.4–6906.8) 5096.0 (3793.6–6398.4) –328.54 (–1551.91 to 894.83); 0.599
n (%) 19 (82.6) 21 (72.4)
Life-H score
10 weeksd 6.2 (5.3–7.1) 6.8 (6.1–7.5) 0.03 (–0.54 to 0.60); 0.907
n (%) 20 (87.0) 26 (81.3)
22 weeksd 6.1 (5.2–7.0) 7.1 (6.5–7.7) 0.21 (–0.34 to 0.76); 0.450
n (%) 21 (91.3) 27 (93.1)
GMFM-66 dimension D, %
10 weekse 90.0 (84.6–95.1) 86.1 (79.0–92.6) 1.19 (–1.70 to 4.08); 0.420
n (%) 23 (100.0) 31 (96.9)
22 weekse 88.3 (82.2–94.1) 87.2 (80.3–93.7) 1.35 (–1.65 to 4.35); 0.379
n (%) 22 (95.7) 29 (100.0)
GMFM-66 dimension E, %
10 weekse 87.7 (80.3–94.6) 84.5 (76.8–91.6) 0.07 (–2.06 to 2.21); 0.948
n (%) 23 (100.0) 31 (96.9)
22 weekse 86.4 (78.5–93.6) 85.7 (78.1–92.7) –0.81 (–3.07 to 1.45); 0.482
n (%) 22 (95.7) 29 (100.0)
Gait speed, m.s–1
10 weeks 1.18 (1.06–1.30) 1.06 (0.95–1.17) –0.06 (–0.18 to 0.06); 0.315
n (%) 23 (100.0) 31 (96.9)
22 weeks 1.12 (1.01–1.24) 1.11 (1.00–1.22) 0.01 (–0.12 to 0.14); 0.834
n (%) 22 (95.7) 29 (100.0)
Maximal voluntary contraction, Nm
10 weeks 32.3 (22.2–42.3) 36.5 (29.6–43.3) 4.36 (–2.17 to 10.88); 0.191
n (%) 21 (91.3) 30 (93.8)
22 weeks 26.8 (19.3–34.3) 34.8 (28.7–41.0) 5.86 (–1.68 to 13.41); 0.128
n (%) 20 (87.0) 28 (96.6)
Data are mean (95% confidence interval [CI]) unless otherwise indicated. aAdjusted for baseline values and Gross Motor Function Classifi-
cation System level. bNumber included in analysis; number as percentage of participants who attended 10 week assessment (n=55). cNum-
ber included in analysis; number as percentage of participants who attended 22 week assessment (n=52). dData transformed using square
root transformation in order to calculate mean and 95% CI. Mean (95% CI) presented on original scale. eData transformed using square
transformation in order to calculate mean and 95% CI. Mean (95% CI) presented on original scale. Life-H, Assessment of Life Habits;
GMFM, Gross Motor Function Measure.
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and that isometric plantarflexor strength explained at least
50% of the variance measures of walking capacity in adults
with CP.26 While this suggests that progressive resistance
training targeted at the ankle plantarflexors may improve
walking capacity in people with CP, our findings do not
support this hypothesis. Similar to our findings, a recent
meta-analysis found no evidence that resistance training
improved gross motor function, gait speed, or participation
in children and adolescents with CP, although only two
studies assessed participation.7 However, it is possible that
the measures of activity used in this study were not sensi-
tive to change, particularly given the high proportion of
individuals in GMFCS level I. Indeed, a ceiling effect was
evident for dimensions D and E of the GMFM-66, as 20%
and 9% of participants achieved the maximum possible
score for dimensions D and E respectively at baseline; all
participants who achieved a maximum score at baseline
were in GMFCS level I.
There is limited evidence available on the biomechanical
effects of progressive resistance training among people with
CP. Without this data, the mechanisms by which muscle
strength, gait efficiency, and gross motor function are
hypothesized to change in people with CP are based on
data in people without CP. Although we hypothesized that
gait efficiency may be improved through a number of
biomechanical mechanisms, we found neither an improve-
ment in underlying biomechanical variables nor gait effi-
ciency. It is therefore unclear if the lack of improvement in
gait efficiency is because these biomechanical variables do
not contribute to gait efficiency in CP or because the pro-
gramme failed to change these variables. However, it
should also be noted that biomechanical variables, includ-
ing muscle strength, were only assessed on one side and, as
two sides were trained, improvements may have been
observed on the unassessed side. Previous studies found evi-
dence that strength training increased gastrocnemius mus-
cle volume in children with CP.27,28 However, these studies
lacked a control group, which is a significant limitation
when determining a causal association as changes in chil-
dren may be due to growth. A recent randomized control
trial of 17 young adults with CP also found changes in
plantarflexor muscle volume in favour of progressive resis-
tance training.29 These changes coincided with improve-
ments in isometric plantarflexor muscle strength, functional
strength, walking endurance, agility, and anaerobic capac-
ity. Unlike the current study however, only individuals in
GMFCS levels I and II were included. Indeed, studies that
found improvements after exercise interventions often
included children in GMFCS level I and II only.29–31
Given the heterogeneity of severity of motor function
and associated impairments in CP, it is likely that the effi-
cacy of progressive resistance training varies between indi-
viduals. We found that the intervention had some positive
effects, when considering effects by GMFCS level and
anatomical distribution (i.e. unilateral and bilateral).
Specifically, we observed more efficient gait at 22 weeks
among individuals with bilateral CP who received the
intervention compared to those who received usual care.
We also found that individuals with unilateral CP in the
intervention group participated in approximately 15 min-
utes more moderate-to-vigorous physical activity per day,
participated in 1000 more steps per day, and
had lower knee flexion angles at 10 weeks, compared to
those who received usual care. Among those in GMFCS
level II, there was some evidence that adolescents in the
intervention group had more efficient gait and greater
muscle strength and muscle volume at 22 weeks compared
to those in the control group. The mean difference of 0.16
in NNcost suggests that the treatment effect may be clini-
cally meaningful for those in GMFCS level II.23 However,
the wide confidence interval indicates the estimate is
imprecise because of the relatively small number of partici-
pants in this subgroup and thus the result may be due to
random error. This result, and others obtained from sub-
group analyses, should be interpreted with caution.
Fifty-six percent of individuals in GMFCS level II had
bilateral CP, suggesting that distribution explains some but
not all of the treatment effect observed in GMFCS level
II. Those in GMFCS level II may represent individuals
with greater capacity for change than individuals in
GMFCS level I, but also with more functional capacity to
recruit muscle fibres than those in GMFCS level III.
Future research should explore the potential benefits of
resistance training for those in GMFCS level II using an
adequate sample size. Other factors that may contribute to
variations in effectiveness of resistance training for individ-
uals include baseline level of muscle strength, selective
motor control, previous treatment, and orthotic use.
Strength or resistance training is one of the most fre-
quently used interventions among physiotherapists to man-
age lower-limb function in adolescents with CP.6 In order
for the findings to be clinically meaningful and to inform
clinical decision making, it is essential to examine the effects
of resistance training under ‘real world’ clinical settings.
This trial was developed based on conditions of routine
clinical practice, while adhering to current recommenda-
tions for resistance training. Participants completed one
supervised session per week and two home sessions per
week as this is a typical model of delivering therapy services
in the United Kingdom and the United States.32 That is,
therapy is often delivered weekly, biweekly, or bimonthly
for a specified period of time to allow the person to progress
towards an established goal.32 Such a model involves input
from a therapist in combination with unsupervised perfor-
mance of exercises by the individual.32 The inclusion of the
home exercise programme was important for delivering
resistance training according to guidelines. A previous study
reported that delivering a home-based programme to ado-
lescents with CP according to resistance training guidelines
was feasible and increased lower limb strength.33 Our find-
ings, however, suggest that this model of delivering resis-
tance training to adolescents with CP does not improve gait
efficiency, ankle plantarflexor muscle strength, activity, or
participation.
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In order to aid interpretation of our findings we moni-
tored attendance at supervised sessions, completion of home
sessions, and progression of exercises. The National
Strength and Conditioning Association recommend young
people with typical development perform between 1 to 3 sets
of 6 to 15 repetitions on 2 to 3 days per week,8 which
equates to between 20 and 90 sets and between 120 and
1350 repetitions over 10 weeks. Based on the combined
attendance at supervised classes and self-reported comple-
tion of home exercise sessions, the median number of sets
performed over 10 weeks was 150 (interquartile range 120–
164) and the median number of repetitions was 1592 (in-
terquartile range 1328–1760). This suggests that participants
received progressive resistance training according to resis-
tance training guidelines for young people with typical
development. While it is possible that variability in comple-
tion of the exercises between participants contributed to the
findings, our per-protocol analysis did not indicate that the
programme was effective among participants with better
adherence. It is possible that a higher dose of resistance
training is required to observe effects. However, at present
there is a lack of research regarding the dose-response rela-
tionship between exercise and outcomes for people with CP.7
All participants in this study progressively increased
resistance throughout the programme. Resistance was
increased at a median of 7 out of 9 possible sessions. The
most frequently reported reasons for not increasing resis-
tance were that the person was reaching fatigue at the pre-
scribed number of repetitions and the person was not
obtaining full range of movement or performing poor
technique at the current resistance. Another reason for
non-progression was an inability to add weight to the
weighted vests because either the vest caused shoulder or
back pain, or the vest was full. This was not necessarily
related to the person’s age or GMFCS level. The potential
for non-progression of resistance when using weighted
vests to deliver resistance training for young people with
CP has not been reported in other studies that have used
weighted vests.33,34 We believe it is important to highlight
this potential barrier to implementing progressive resis-
tance training for adolescents with CP in clinical practice.
Access to weight machines may be required to continu-
ously increase resistance to a sufficient level to obtain large
and consistent changes in muscle strength. This may be
the case for all individuals with CP as their muscle
strength increases during the programme, but particularly
for those with relatively high baseline levels of strength.
A recent randomized controlled trial found that progres-
sive resistance training for young adults with CP aged 15 to
30 years in GMFCS level I or II delivered in a community
gymnasium improved muscle strength and 6-minute walk
test distance.29 An earlier randomized controlled trial found
that progressive resistance training for young adults with
CP aged 14 to 22 years in GMFCS level II or III delivered
in a community gymnasium improved muscle strength but
not 6-minute walk test distance or score on dimensions D
or E of the GMFM.35 These studies suggest that
progressive resistance training delivered two to three times
per week in a community gymnasium improves muscle
strength and may improve mobility. However, participants
in these studies were older than those included in the pre-
sent study. The findings of these studies may not be appli-
cable to this younger population, and if they are, delivering
resistance training to adolescents aged 10 to 14 years in a
gymnasium may not be feasible. Indeed, interviews with
adolescents in our study revealed that they strongly valued
supervision from a physiotherapist and they faced several
barriers to participating in resistance training in a commu-
nity gymnasium, including being unable to access gyms
because of their age. Participants and physiotherapists also
indicated they did not think it was feasible to attend or deli-
ver more than one supervised session per week. We will
outline our findings from interviews in detail elsewhere.
This study addresses several gaps in the evidence base
outlined by a Cochrane review,7 including provision of an
intervention in accordance with evidence-based guidelines,8
assessment of activity and participation, systematic record-
ing of adverse events, and investigation of changes in
biomechanical variables. However, there are potential limi-
tations to the study. Participants did not necessarily pre-
sent with reduced muscle strength or inefficient gait.
Although the presence of these complaints may have been
a reason that adolescents volunteered to participate, it was
not an inclusion criteria. This may explain variability in
the effects and it is possible that the intervention is effec-
tive in those who present with inefficient gait or reduced
strength. Although this is the largest study of progressive
resistance training among people with CP to date, it is still
limited by a relatively small sample size and missing data
in some variables, particularly medial gastrocnemius muscle
volume and ankle and knee flexion angle. Data on adher-
ence to the home exercise programme is based on self-
report and may be subject to bias. We did not control the
usual care received by the two groups, apart from prevent-
ing the usual care control group from receiving progressive
resistance training. It is possible that the lack of a differ-
ence in outcomes between the two groups was because the
control group received other intervention. However, stud-
ies of resistance training for CP often compare resistance
training to ‘usual care’ without describing usual care. Thus,
we believe the description of usual care in this study is
important for interpreting the findings. We also did not
monitor or prevent orthotic use, which may have impacted
gains in strength made during training. Further, subgroup
analyses should be interpreted with caution given the rela-
tively small sample in each subgroup and the lack of preci-
sion of effect estimates. Finally, the applicability of the
findings are limited to ambulatory individuals with CP.
In conclusion, the findings indicate that a physiothera-
pist-led progressive resistance training programme of the
ankle plantarflexors, delivered through a combination of
supervised sessions and a home programme over 10 weeks,
does not improve gait efficiency, muscle strength, activity,
or participation. These findings have implications for
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delivery of progressive resistance training. Previous
research suggests that delivery of progressive resistance
training through supervised sessions in community gymna-
siums improves muscle strength.29,35 Future research
should examine the dose–response relationship between
resistance training and outcomes, and sustainable models
of delivering progressive resistance training to children and
adolescents with CP in the community.
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